Psilocybin is a natural psychedelic compound found in certain species of mushroom (psilocybe), often referred to as «magic mushrooms» or «hallucinogenic mushrooms».
It is known for its psychoactive properties, which can induce altered states of consciousness, visual and auditory hallucinations and changes in perception, mood and thought processes.
Therapeutic potential : Recent studies have shown that psilocybin has significant potential in the treatment of mental disorders such as depression, anxiety, post-traumatic stress disorder and drug addiction. Clinical trials are underway to better understand its efficacy and safety.
Revolutionary therapy designation: The US Food and Drug Administration (FDA) has granted psilocybin «breakthrough therapy» status for certain treatments, underlining its potential as a promising therapeutic option.
Decriminalisation and legalisation: Various jurisdictions around the world are re-evaluating the legal status of psilocybin. Some places have decriminalized its use, and there are moves to legalize it for medical and therapeutic purposes.
Regulatory updates : Following the evolution of laws and regulations helps us understand how psilocybin can be accessed and used legally.
Mechanisms of action : Ongoing research is exploring how psilocybin functions in the brain, including its interaction with serotonin receptors and its impact on brain connectivity and neuronal plasticity.
Long-term effects : Studies on the short- and long-term effects of psilocybin are essential to assess its safety profile.
Cultural changes : Perceptions of psychedelics, including psilocybin, are changing. More and more people are interested in its potential benefits, and this is influencing cultural attitudes and political decisions.
Ethical and social implications : Understanding the wider impact of psilocybin use on society, including ethical considerations and social dynamics, is important for making informed decisions.
The Drug Enforcement Administration (DEA) has finalized its 2026 production quotas for controlled substances, confirming a significant increase in the legal manufacture of...
The Czech Chamber of Deputies has approved by a clear majority of 142 out of 159 deputies the reform of the Czech penal code, which includes a relaxation...
PATOO, a Jamaican brand of psychedelic products, has announced a partnership with Fontana Pharmacy, the island's largest drugstore chain. This collaboration introduces the...
New Zealand's Ministry of Health has for the first time granted cultivation authorization for research on an indigenous magic mushroom, Psilocybe...
A campaign to decriminalize hallucinogenic mushrooms has been given the green light by California's Secretary of State to begin collecting signatures for...
Australia has become the first country in the world to legalize the use of psychedelics to treat certain mental disorders. Under the new regulations, which are...
A Rhode Island House committee has approved a bill that would legalize the possession and cultivation of psilocybin mushrooms,...
While Oregon has decriminalized small amounts of psilocybin and authorized the first psilocybin therapy center in the U.S., its prices have been...
Psilocybin is a psychotropic compound found naturally in certain species of mushrooms, commonly known as «magic mushrooms», «hallucinogenic mushrooms» or «shrooms». It belongs to the...
Oregon authorities last week issued the first commercial license under the state's psilocybin therapy program. The...
Several US states are working to amend their legislation on psychedelics. Here's a look at the latest developments. Hawaii to create task force on psychedelic...
In Australia, licensed psychiatrists will be able to prescribe MDMA and psilocybin, the active ingredient in magic mushrooms, from July 2023. The Therapeutic...
A Portland herbalist shop is openly selling psilocybin mushrooms, attracting lines of more than two hours to get their hands on several varieties of...
On Tuesday, Colorado voters approved an initiative to legalize the possession of certain psychedelics and create «healing centers» a la...
A multi-center clinical trial conducted by COMPASS Pathways at 22 international sites, including the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London and the...
A pharmaceutical company called Apex Labs announced on November 1 that it would conduct the first North American clinical trial of multidose psilocybin prescribed at home. Apex...
Researchers associated with the University of Plymouth are to launch a ground-breaking study to investigate previously untested hypotheses about the origin of psychedelic compounds in...
Researchers affiliated with the University of Copenhagen are investigating psilocybin as a possible treatment for obesity. Previous research on psilocybin and other psychedelic substances has shown...
The San Francisco Board of Supervisors last Wednesday unanimously approved a resolution decriminalizing entheogens and their compounds for adults....
Psilocybin, the active ingredient in hallucinogenic mushrooms, has already attracted a great deal of interest for its therapeutic potential in a variety of contexts, including helping people...
